参考文献：
▪ *87.6%数据来源《2023国人“肠“烦恼及益生菌消费洞察报告》
▪ Plein K, Hotz J. “Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea-a pilot study.” Z Gastroenterol. 1993;31:129-134.
▪Guslandi M, Mezzi G, Sorghi M, et al. “Saccharomyces boulardii in maintenance treatment of Crohn’s disease.” Dig Dis Sci. 2000;45:1462-1464.
▪ Saskia Thomas, Diana Metzke, Jürgen Schmitz, Yvonne Dörffel, and Daniel C. Baumgart. “Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis.”
▪ Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics—Saccharomyces boulardii. Aliment Pharmacol Ther. 2007;26(6):767-778.
▪ Castagliuolo I, LaMont JT, Nikulasson ST, et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996;64(7):2780-2784.
▪ Shoda R, Mutai M, Sato Y, et al. Efficacy of Bifidobacterium breve and Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea in Helicobacter pylori eradication therapy. Helicobacter. 2006;11(4):211-217.
▪Kahan S, Reynaud J, Rawat A, et al. Inhibition of pathogens by Saccharomyces boulardii may involve alterations in the gut epithelial tight junction proteins. Gut Microbes. 2013;4(5):413-422.
